---
title: "Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination: Clinical trials questions"
description: "Clinical trials questions on Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results and Long-term results. Questions: Gardasil 9 vs Gardasil in women 16-26: efficacy against HPV 31-58 disease? Did Gardasil 9 reduce HPV 31-58-related Pap abnormalities and procedures vs Gardasil? Gardasil 9 vs Gardasil: were antibody responses to HPV 6, 11, 16, 18 non-inferior? How was Gardasil 9 effectiveness inferred in children 9 to 15? 9 further questions follow. 13 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination: Clinical trials questions

Manufacturer: Merck Sharp & Dohme LLC  
Prescribing information: [Gardasil 9](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf)

Clinical trials questions that apply to every indication of Gardasil 9 are on [Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), all indications: Clinical trials](https://www.evicenter.com/medical-information/gardasil-9/clinical-trials).

## Study results

<a id="gardasil9-efficacy-hpv-31-58"></a>

### Gardasil 9 vs Gardasil in women 16-26: efficacy against HPV 31-58 disease?

Applies to: Girls and women 16 through 26 years of age (Study 1, Gardasil 9 compared with Gardasil)

> “The efficacy of GARDASIL 9 in 16- through 26-year-old girls and women was assessed in an active
> comparator-controlled, double-blind, randomized clinical trial (Study 1) that included a total of 14,204
> women (GARDASIL 9 = 7,099; GARDASIL = 7,105) who were enrolled and vaccinated without pre-
> screening for the presence of HPV infection. Subjects were followed up with a median duration of 40
> months (range 0 to 64 months) after the last vaccination.”

Source: [GARDASIL 9: Prescribing information, page 16, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=16)

> “Table 7: Analysis of Efficacy of GARDASIL 9 against HPV Types 31, 33, 45, 52, and 58 in the PPE* Population of 16-
>  through 26-Year-old Girls and Women (Study 1)
> Disease Endpoint
> GARDASIL 9 
> N<sup>†</sup>=7099 
> GARDASIL 
> N<sup>†</sup>=7105 
> GARDASIL 9
> Efficacy
> %
> (95% CI)
> n<sup>‡</sup>
>  Number of
> cases 
> n<sup>‡</sup>
> Number of 
> cases 
> HPV 31-, 33-, 45-, 52-, 58-related CIN 2/3, AIS, Cervical
> Cancer, VIN 2/3, VaIN 2/3, Vulvar Cancer, and Vaginal
> Cancer 
> 6016 
> 1 
> 6017 
> 30
> 96.7
> (80.9, 99.8)
> HPV 31-, 33-, 45-, 52-, 58-related CIN 1 
> 5948 
> 1 
> 5943 
> 69
> 98.6
> (92.4, 99.9)
> HPV 31-, 33-, 45-, 52-, 58-related CIN 2/3 or AIS 
> 5948 
> 1 
> 5943 
> 27
> 96.3
> (79.5, 99.8)
> HPV 31-, 33-, 45-, 52-, 58-related Vulvar or Vaginal Disease 
> 6009 
> 1 
> 6012 
> 16
> 93.8
> (61.5, 99.7)”

Source: [GARDASIL 9: Prescribing information, page 17, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=17)

> “*The PPE population consisted of individuals who received all three vaccinations within one year of enrollment, did not have major
> deviations from the study protocol, were naïve (PCR negative and seronegative) to the relevant HPV type(s) (Types 31, 33, 45, 52,
> and 58) prior to dose 1, and who remained PCR negative to the relevant HPV type(s) through one month post-dose 3 (Month 7);
> data from Study 1 (NCT00543543).”

Source: [GARDASIL 9: Prescribing information, page 17, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=17)

<a id="gardasil9-pap-tests-procedures"></a>

### Did Gardasil 9 reduce HPV 31-58-related Pap abnormalities and procedures vs Gardasil?

Applies to: Girls and women 16 through 26 years of age (Study 1, Gardasil 9 compared with Gardasil)

> “The efficacy of GARDASIL 9 in 16- through 26-year-old girls and women was assessed in an active
> comparator-controlled, double-blind, randomized clinical trial (Study 1) that included a total of 14,204
> women (GARDASIL 9 = 7,099; GARDASIL = 7,105) who were enrolled and vaccinated without pre-
> screening for the presence of HPV infection. Subjects were followed up with a median duration of 40
> months (range 0 to 64 months) after the last vaccination.”

Source: [GARDASIL 9: Prescribing information, page 16, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=16)

> “Efficacy for all endpoints was
> measured starting after the Month 7 visit.”

Source: [GARDASIL 9: Prescribing information, page 16, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=16)

> “GARDASIL 9 prevented HPV 31-, 33-, 45-, 52-, and 58-related persistent infection and disease and
> also reduced the incidence of HPV 31-, 33-, 45-, 52-, and 58-related Pap test abnormalities, cervical and
> external genital biopsy, and definitive therapy (Table 7).”

Source: [GARDASIL 9: Prescribing information, page 16, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=16)

> “Table 7: Analysis of Efficacy of GARDASIL 9 against HPV Types 31, 33, 45, 52, and 58 in the PPE* Population of 16-
>  through 26-Year-old Girls and Women (Study 1)
> Disease Endpoint
> GARDASIL 9 
> N<sup>†</sup>=7099 
> GARDASIL 
> N<sup>†</sup>=7105 
> GARDASIL 9
> Efficacy
> %
> (95% CI)
> n<sup>‡</sup>
>  Number of
> cases 
> n<sup>‡</sup>
> Number of 
> cases”

Source: [GARDASIL 9: Prescribing information, page 17, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=17)

> “HPV 31-, 33-, 45-, 52-, 58-related ASC-US HR-HPV Positive
> or Worse Pap<sup>#</sup> Abnormality 
> 5881 
> 35 
> 5882 
> 462
> 92.6
> (89.7, 94.8)
> HPV 31-, 33-, 45-, 52-, 58-related Biopsy 
> 6016 
> 7 
> 6017 
> 222
> 96.9
> (93.6, 98.6)
> HPV 31-, 33-, 45-, 52-, 58-related Definitive TherapyÞ 
> 6012 
> 4 
> 6014 
> 32
> 87.5
> (65.7, 96.0)”

Source: [GARDASIL 9: Prescribing information, page 17, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=17)

> “ÞIncluding loop electrosurgical excision procedure (LEEP) and conization”

Source: [GARDASIL 9: Prescribing information, page 17, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=17)

<a id="gardasil9-immune-response-vs-gardasil"></a>

### Gardasil 9 vs Gardasil: were antibody responses to HPV 6, 11, 16, 18 non-inferior?

Applies to: Girls 9 through 15 years of age (Study 3) and girls and women 16 through 26 years of age (Study 1), Gardasil 9 compared with Gardasil

> “Effectiveness of GARDASIL 9 against persistent infection and disease related to HPV Types 6, 11, 16,
> or 18 was inferred from non-inferiority comparisons in Study 1 (16- through 26-year-old girls and women)
> and Study 3 (9- through 15-year-old girls) of GMTs following vaccination with GARDASIL 9 with those
> following vaccination with GARDASIL. A low number of efficacy endpoint cases related to HPV types 6,
> 11, 16 and 18 in both vaccination groups precluded a meaningful assessment of efficacy using disease
> endpoints associated with these HPV types.”

Source: [GARDASIL 9: Prescribing information, page 18, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=18)

> “Anti-HPV 6, 11, 16 and 18 GMTs at Month 7 for GARDASIL 9 among girls 9 through 15 years of age
> and young women 16 through 26 years of age were non-inferior to those among the corresponding
> populations for GARDASIL (Table 8). At least 99.7% of individuals included in the analyses for each HPV
> type became seropositive by Month 7.”

Source: [GARDASIL 9: Prescribing information, page 18, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=18)

<a id="gardasil9-children-9-15-effectiveness"></a>

### How was Gardasil 9 effectiveness inferred in children 9 to 15?

Applies to: Girls and boys 9 through 15 years of age

> “Effectiveness of GARDASIL 9 against persistent infection and disease related to vaccine HPV types in
> 9- through 15-year-old girls and boys was inferred from non-inferiority comparison conducted in the PPI
> population in Study 2 of GMTs following vaccination with GARDASIL 9 among 9- through 15-year-old girls
> and boys with those among 16- through 26-year-old girls and women. Anti-HPV GMTs at Month 7 among
> 9- through 15-year-old girls and boys were non-inferior to anti-HPV GMTs among 16- through 26-year-old
> girls and women (Table 9).”

Source: [GARDASIL 9: Prescribing information, page 19, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=19)

<a id="gardasil9-two-dose-schedule"></a>

### How was 2-dose Gardasil 9 effectiveness inferred in ages 9 to 14?

Applies to: Girls and boys 9 through 14 years of age given the 2-dose regimen (Study 8)

> “Effectiveness of GARDASIL 9 against persistent infection and disease related to vaccine HPV types in
> 9- through 14-year-old girls and boys who received a 2-dose regimen was inferred from non-inferiority
> comparison conducted in the PPI population in Study 8 of GMTs following vaccination with GARDASIL 9
> among 9- through 14-year-old girls and boys who received a 2-dose regimen (at 0, 6 months or 0, 12
> months) with those among 16- through 26-year-old girls and women who received a 3-dose regimen (at
> 0, 2, 6 months). Anti-HPV GMTs at one month after the last dose among 9- through 14-year-old girls and
> boys who received 2 doses of GARDASIL 9 were non-inferior to anti-HPV GMTs among 16- through 26-
> year-old girls and women who received 3 doses of GARDASIL 9 (Table 12).
> One month following the last dose of the assigned regimen, between 97.9% and 100% of subjects
> across all groups became seropositive for antibodies against the 9 vaccine HPV types (Table 12). 
> In the same study, in girls and boys 9 through 14 years old, GMTs at one month after the last vaccine
> dose were numerically lower for some vaccine types after a 2-dose schedule than in girls 9 through 14
> years old after a 3-dose schedule (HPV types 18, 31, 45, and 52 after 0, 6 months and HPV type 45 after
> 0, 12 months; Table 12). The clinical relevance of these findings is unknown.
> Duration of immunity of a 2-dose schedule of GARDASIL 9 has not been established.”

Source: [GARDASIL 9: Prescribing information, page 23, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=23)

<a id="gardasil9-males-16-26-effectiveness"></a>

### How was Gardasil 9 effectiveness inferred in males 16 to 26?

Applies to: Boys and men 16 through 26 years of age (Study 7)

> “Study 7 evaluated immunogenicity of GARDASIL 9 in
> boys and men, including 1,106 self-identified as heterosexual men (HM) and 313 self-identified as men
> having sex with men (MSM), 16 through 26 years of age at enrollment (mean ages 20.8 years and 22.2
> years, respectively) and 1,101 girls and women 16 through 26 years of age at enrollment (mean age 21.3
> years).”

Source: [GARDASIL 9: Prescribing information, page 16, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=16)

> “Effectiveness of GARDASIL 9 against persistent infection and disease related to vaccine HPV types in
> 16- through 26-year-old boys and men was inferred from non-inferiority comparison conducted in the PPI
> population in Study 7 of GMTs following vaccination with GARDASIL 9 among 16- through 26-year-old
> HM with those among 16- through 26-year-old girls and women. Anti-HPV GMTs at Month 7 among 16-
> through 26-year-old HM were non-inferior to anti-HPV GMTs among 16- through 26-year-old girls and
> women (Table 10). Study 7 also enrolled 313 16- through 26-year-old HIV-negative MSM. At Month 7,
> anti-HPV GMT ratios for MSM relative to HM ranged from 0.6 to 0.8, depending on HPV type. The GMT
> ratios for MSM relative to HM were generally similar to those previously observed in clinical trials with
> GARDASIL.”

Source: [GARDASIL 9: Prescribing information, page 20, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=20)

<a id="gardasil9-women-27-45-effectiveness"></a>

### How was Gardasil 9 effectiveness supported in women 27 to 45?

Applies to: Women 27 through 45 years of age (Study 9 immunobridging)

> “In women 27-45, effectiveness of GARDASIL 9 was supported by immunobridging comparisons to women 16-26, and supported by immunogenicity data.”

Source: [GARDASIL 9: Efficacy of GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant), captured 2026-11-13](https://www.merckvaccines.com/gardasil9/efficacy/#:~:text=In%20women%2027%2D45%2C%20effectiveness%20of,and%20supported%20by%20immunogenicity%20data.)

> “Effectiveness of GARDASIL 9 against persistent infection and disease related to vaccine HPV types in
> 27- through 45-year-old women was supported by immunobridging comparisons conducted in the PPI
> population in Study 9. In Study 9, the GMT ratios of anti-HPV responses at Month 7 among 27- through
> 45-year-old women relative to anti-HPV responses among 16- through 26-year-old girls and women met
> the success criteria of having the lower bound of the 95% CI of the GMT ratios greater than 0.50 for HPV
> 16, 18, 31, 33, 45, 52, and 58 (Table 11).”

Source: [GARDASIL 9: Prescribing information, page 21, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=21)

<a id="gardasil9-gardasil-women-16-26"></a>

### How effective was Gardasil, the predecessor of Gardasil 9, in women 16 to 26?

Applies to: GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9

> “Efficacy and effectiveness of GARDASIL are relevant to GARDASIL 9 since the vaccines are
> manufactured similarly and contain four of the same HPV L1 VLPs.”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

> “Efficacy of GARDASIL was assessed in five AAHS-controlled, double-blind, randomized clinical trials
> evaluating 24,596 individuals 16 through 26 years of age (20,541 girls and women and 4,055 boys and
> men). The results of these trials are shown in Table 6 below.”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

> “Table 6: Analysis of Efficacy of GARDASIL in the PPE* Population for Vaccine HPV Types
> Disease Endpoints 
> GARDASIL 
> AAHS Control
> % Efficacy (95% CI)
> N
> Number of
> cases 
> N
> Number of 
> cases
> 16- through 26-Year-Old Girls and Women<sup>†</sup>
> HPV 16- or 18-related CIN 2/3 or AIS 
> 8493
> 2
> 8464
> 112
> 98.2 (93.5, 99.8)
> HPV 16- or 18-related VIN 2/3 
> 7772
> 0
> 7744
> 10
> 100.0 (55.5, 100.0)
> HPV 16- or 18-related VaIN 2/3 
> 7772
> 0
> 7744
> 9
> 100.0 (49.5, 100.0)
> HPV 6-, 11-, 16-, or 18-related CIN (CIN
> 1, CIN 2/3) or AIS 
> 7864
> 9
> 7865
> 225
> 96.0 (92.3, 98.2)
> HPV 6-, 11-, 16-, or 18-related Genital
> Warts 
> 7900
> 2
> 7902
> 193
> 99.0 (96.2, 99.9)
> HPV 6- and 11-related Genital Warts 
> 6932
> 2
> 6856
> 189
> 99.0 (96.2, 99.9)”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

> “*The PPE population consisted of individuals who received all three vaccinations within one year of enrollment, did not have major
> deviations from the study protocol, were naïve (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and
> 18) prior to dose 1 and who remained PCR negative to the relevant HPV type(s) through one month post-dose 3 (Month 7).”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

> “N=Number of individuals with at least one follow-up visit after Month 7”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

> “Note 1: Point estimates and confidence intervals are adjusted for person-time of follow-up.”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

> “Note 2: Table 6 does not include cases due to HPV types not covered by the vaccine.”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

Note: The label does not state the follow-up duration for the Table 6 trials.

<a id="gardasil9-gardasil-males-16-26"></a>

### How effective was Gardasil (predecessor vaccine) against genital and anal lesions in males 16-26?

Applies to: GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9

> “Efficacy and effectiveness of GARDASIL are relevant to GARDASIL 9 since the vaccines are
> manufactured similarly and contain four of the same HPV L1 VLPs.”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

> “Table 6: Analysis of Efficacy of GARDASIL in the PPE* Population for Vaccine HPV Types
> Disease Endpoints 
> GARDASIL 
> AAHS Control
> % Efficacy (95% CI)
> N
> Number of
> cases 
> N
> Number of 
> cases”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

> “16- through 26-Year-Old Boys and Men
> External Genital Lesions HPV 6-, 11-, 16-, or 18-related
> External Genital Lesions 
> 1394 
> 3
> 1404 
> 32 
> 90.6 (70.1, 98.2)
> Condyloma  
> 1394 
> 3
> 1404 
> 28 
> 89.3 (65.3, 97.9)
> PIN 1/2/3 
> 1394 
> 0
> 1404 
> 4 
> 100.0 (-52.1, 100.0)
> HPV 6-, 11-, 16-, or 18-related Endpoint
> AIN 1/2/3 
> 194 
> 5
> 208 
> 24 
> 77.5 (39.6, 93.3)
> AIN 2/3 
> 194 
> 3
> 208 
> 13 
> 74.9 (8.8, 95.4)
> AIN 1 
> Condyloma Acuminatum 
> Non-acuminate 
> 194 
> 194 
> 194 
> 4
> 0
> 4
> 208 
> 208 
> 208 
> 16 
> 6 
> 11 
> 73.0 (16.3, 93.4)
> 100.0 (8.2, 100.0)
> 60.4 (-33.5, 90.8)”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

> “*The PPE population consisted of individuals who received all three vaccinations within one year of enrollment, did not have major
> deviations from the study protocol, were naïve (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and
> 18) prior to dose 1 and who remained PCR negative to the relevant HPV type(s) through one month post-dose 3 (Month 7).”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

> “N=Number of individuals with at least one follow-up visit after Month 7”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

> “Note 1: Point estimates and confidence intervals are adjusted for person-time of follow-up.”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

> “Note 2: Table 6 does not include cases due to HPV types not covered by the vaccine.”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

Note: The label does not state the follow-up duration for the Table 6 trials.

<a id="gardasil9-gardasil-women-27-45"></a>

### How effective was Gardasil (predecessor vaccine) in women 27 to 45?

Applies to: GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9

> “Efficacy and effectiveness of GARDASIL are relevant to GARDASIL 9 since the vaccines are
> manufactured similarly and contain four of the same HPV L1 VLPs.”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

> “A clinical trial evaluated efficacy of GARDASIL in 3,253 women 27 through 45 years of age, based on
> a combined endpoint of HPV 6-, 11-, 16- or 18-related persistent infection, genital warts, vulvar and
> vaginal dysplastic lesions of any grade, CIN of any grade, AIS, and cervical cancer. These women were
> randomized 1:1 to receive either GARDASIL or AAHS control.”

Source: [GARDASIL 9: Prescribing information, page 14, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=14)

> “In the base study (median duration of follow-up of 3.5 years post-dose 3), the efficacy of GARDASIL
> against the combined incidence of HPV 6-, 11-, 16-, and 18-related persistent infection, genital warts,
> VIN, VaIN, vulvar cancer, vaginal cancer, cervical dysplasia (any grade CIN), AIS and cervical cancer in
> the PPE population was 87.7% (95% CI: 75.4%, 94.6%). The efficacy estimate for the combined endpoint
> was driven primarily by prevention of persistent infection. The efficacy of GARDASIL against the
> combined incidence of HPV 6-, 11-, 16-, and 18-related genital warts or cervical dysplasia was 95.0%
> (95% CI: 68.7%, 99.9%) in the PPE population. While no statistically significant efficacy was
> demonstrated for GARDASIL in the base study for prevention of cervical intraepithelial neoplasia grades
> 2 and 3 (CIN 2/3), adenocarcinoma in situ (AIS) or cervical cancer related to HPV types 16 and 18, there
> was 1 case of CIN 2/3 observed in the GARDASIL group and 5 cases in the placebo group. The CIN 2
> case in the GARDASIL group tested positive by PCR for HPV 16 and HPV 51.”

Source: [GARDASIL 9: Prescribing information, page 14, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=14)

> “In the long-term extension of this study, subjects from Colombia (n=600) randomized to the
> GARDASIL group in the base study were monitored for HPV 6-, 11-, 16-, and 18-related genital warts or
> cervical dysplasia. The median follow-up post-dose 3 was 8.9 years with a range of 0.1 to 10.1 years over”

Source: [GARDASIL 9: Prescribing information, page 14, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=14)

> “a total of 3,518 person-years. During the long-term extension phase, no cases of HPV 6-, 11-, 16-, or 18-
> related CIN (any grade) or genital warts were observed in the PPE population.”

Source: [GARDASIL 9: Prescribing information, page 15, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=15)

<a id="gardasil9-gardasil-men-27-45"></a>

### How was Gardasil (predecessor vaccine) effectiveness inferred in men 27 to 45?

Applies to: GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9

> “Efficacy and effectiveness of GARDASIL are relevant to GARDASIL 9 since the vaccines are
> manufactured similarly and contain four of the same HPV L1 VLPs.”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

> “Effectiveness of GARDASIL in men 27 through 45 years of age is inferred from efficacy data in women
> 27 through 45 years of age as described above and supported by immunogenicity data from a clinical trial
> in which 150 men, 27 through 45 years of age, received a 3-dose regimen of GARDASIL (0, 2, 6 months).
> A cross-study analysis of per-protocol immunogenicity populations compared Month 7 anti-HPV 6, 11, 16,
> and 18 GMTs of these 27- through 45-year-old men (Study A) to those of 16- through 26-year old boys
> and men (Study B) in whom efficacy of GARDASIL had been established (see Table 6). GMT ratios
> (Study A/Study B) for HPV 6, 11, 16, and 18 were 0.82 (95%CI: 0.65, 1.03), 0.79 (95%CI: 0.66, 0.93),
> 0.91 (95%CI: 0.72, 1.13), and 0.74 (95%CI: 0.59, 0.92), respectively.”

Source: [GARDASIL 9: Prescribing information, page 15, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=15)

## Long-term results

<a id="gardasil9-long-term-follow-up"></a>

### What did 10-year follow-up show after Gardasil 9 in ages 9 to 15?

Applies to: Girls and boys 9 through 15 years of age

> “In an extension study of individuals in Study 2, 971 girls and 301 boys 9 through 15 years of age at
> enrollment who received a 3-dose regimen of GARDASIL 9 were actively followed from age 16 onwards
> for endpoint cases of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related persistent infection and
> disease. For girls, disease endpoints assessed included HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-
> related CIN (any grade), AIS, VIN, VaIN, external genital warts, cervical cancer, vulvar cancer and vaginal
> cancer. For boys, the disease endpoints assessed included HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and
> 58-related PIN, external genital warts, penile cancer, perineal cancer and perianal cancer.
> Analysis of the per-protocol population included 872 girls and 262 boys who completed the
> GARDASIL 9 vaccination series within one year, were seronegative to the relevant HPV type at initiation
> of the vaccination series and had not initiated sexual activity prior to receiving the third dose of
> GARDASIL 9. The median follow-up from the last dose of vaccine was 10.0 years with a range of 3.0 to
> 11.0 years in girls 9 through 15 years of age and 9.9 years with a range of 3.0 to 10.6 years in boys 9
> through 15 years of age.
> In girls, no cases of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related CIN 2/3, AIS, VIN, VaIN,
> external genital warts, cervical cancer, vulvar cancer or vaginal cancer were observed over a total of
> 4,576.1 person-years at risk. One case of CIN1 that tested positive for HPV 16, 39 and 59 by PCR was
> observed. In boys, no cases of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related PIN, external
> genital warts, penile cancer, perineal cancer or perianal cancer were observed over a total of 1,278.6
> person-years at risk.”

Source: [GARDASIL 9: Prescribing information, page 17, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=17)

> “In an extension study of individuals in Study 2, among girls and boys 9 through 15 years of age at
> enrollment (range of 494 to 525 subjects with evaluable data across HPV types) and followed for 10 years
> post dose 3, anti-HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58 GMTs as measured by cLIA were decreased
> compared with corresponding values at one-month post-dose 3. The proportion of seropositive subjects
> ranged from 99.6% to 100% at one month post-dose 3 and from 81.3% to 97.7% at 10 years post-dose 3,
> depending on HPV type.”

Source: [GARDASIL 9: Prescribing information, page 22, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=22)

<a id="gardasil9-gardasil-long-term-follow-up"></a>

### What did long-term follow-up of Gardasil (predecessor vaccine) show?

Applies to: GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9

> “Efficacy and effectiveness of GARDASIL are relevant to GARDASIL 9 since the vaccines are
> manufactured similarly and contain four of the same HPV L1 VLPs.”

Source: [GARDASIL 9: Prescribing information, page 13, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=13)

> “In an extension study in females 16 through 26 years of age at enrollment, prophylactic efficacy of
> GARDASIL through Month 60 against overall cervical and genital disease related to HPV 6, 11, 16, and
> 18 was 100% (95% CI: 12.3%, 100%) compared to AAHS control.”

Source: [GARDASIL 9: Prescribing information, page 14, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=14)

> “An extension study in girls and women 16 through 23 years of age used national health care registries
> in Denmark, Iceland, Norway, and Sweden to monitor endpoint cases of HPV 6-, 11-, 16-, or 18-related
> CIN (any grade), AIS, cervical cancer, vulvar cancer, or vaginal cancer among 2,650 girls and women 16
> through 23 years of age at enrollment who were randomized to vaccination with GARDASIL. An interim
> analysis of the per-protocol effectiveness population included 1,902 subjects who completed the
> GARDASIL vaccination series within one year, were naïve to the relevant HPV type through 1 month
> post-dose 3, had no protocol violations, and had follow-up data available. The median follow-up from the
> first dose of vaccine was 6.7 years with a range of 2.8 to 8.4 years. At the time of interim analysis, no
> cases of HPV 6-, 11-, 16-, or 18-related CIN (any grade), AIS, cervical cancer, vulvar cancer, or vaginal
> cancer were observed over a total of 5,765 person-years at risk.”

Source: [GARDASIL 9: Prescribing information, page 14, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=14)

> “An extension study of 614 girls and 565 boys 9 through 15 years of age at enrollment who were
> randomized to vaccination with GARDASIL actively followed subjects for endpoint cases of HPV 6-, 11-,
> 16-, or 18-related persistent infection, CIN (any grade), AIS, VIN, VaIN, cervical cancer, vulvar cancer,
> vaginal cancer, and external genital lesions from the initiation of sexual activity or age 16 onwards. An
> interim analysis of the per-protocol effectiveness population included 246 girls and 168 boys who
> completed the GARDASIL vaccination series within one year, were seronegative to the relevant HPV
> type at initiation of the vaccination series, and had not initiated sexual activity prior to receiving the third
> dose of GARDASIL. The median follow-up from the first dose of vaccine was 7.2 years with a range of
> 0.5 to 8.5 years. At the time of interim analysis, no cases of persistent infection of at least 12 months’
> duration and no cases of HPV 6-, 11-, 16-, or 18-related CIN (any grade), AIS, VIN, VaIN, cervical
> cancer, vulvar cancer, vaginal cancer, or external genital lesions were observed over a total 1,105
> person-years at risk. There were 4 cases of HPV 6-, 11-, 16-, or 18-related persistent infection of at least
> 6 months’ duration, including 3 cases related to HPV 16 and 1 case related to HPV 6, none of which
> persisted to 12 months’ duration.”

Source: [GARDASIL 9: Prescribing information, page 14, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=14)

## Related pages
- [Medical information: Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant): Human papillomavirus vaccination](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination)
- [Indication](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/indication)
- [Real-world evidence](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/safety)
- [Specific populations](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/guidelines)
